Impact Biomedical (IBO) Net Income towards Common Stockholders (2022 - 2026)

Impact Biomedical (IBO) has 5 years of Net Income towards Common Stockholders data on file, last reported at -$2.3 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 78.72% year-over-year to -$2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$18.1 million (up 27.61% YoY) and the FY2024 annual result came in at -$24.8 million, down 471.26% from the prior year.
• Net Income towards Common Stockholders declined to -$2.3 million in Q1 2026, from -$1.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $4.2 million in Q3 2024 to a low of -$27.1 million in Q4 2024.
• A 5-year average of -$3.6 million and a median of -$1.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 465.49% in 2024, down 2094.33% in 2024.
• Tracing IBO's Net Income towards Common Stockholders over 5 years: stood at -$3.4 million in 2022, then surged by 63.27% to -$1.2 million in 2023, then sank by 2094.33% to -$27.1 million in 2024, then soared by 94.56% to -$1.5 million in 2025, then sank by 54.85% to -$2.3 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.3 million (Q1 2026), -$1.5 million (Q3 2025), and -$14.4 million (Q2 2025), per Business Quant data.